Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy.
- Author:
Yan-feng LI
;
Fang-fang GE
;
Yong ZHANG
;
Hui YOU
;
Zhen-xin ZHANG
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Amyloid beta-Peptides; cerebrospinal fluid; Apolipoproteins E; genetics; Biomarkers; cerebrospinal fluid; Cerebral Amyloid Angiopathy; cerebrospinal fluid; Dementia; cerebrospinal fluid; Humans; Male; tau Proteins; cerebrospinal fluid
- From: Chinese Medical Sciences Journal 2015;30(3):170-173
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo study the changes of biomarkers in cerebrospinal fluid (CSF) in cerebral amyloid angiopathy (CAA) dementia and Alzheimer(')s disease.
METHODSLevels of amyloid protein β (Aβ42, Aβ40) and phosphorylated Tau-protein (P-tau) in CSF and ratio of Aβ42/Aβ40 were tested in 5 cases with CAA dementia and 20 cases with Alzheimer's disease collected at Peking Union Medical College Hospital from December 2001 to March 2011.
RESULTSThe levels of Aβ42, Aβ40, and P-tau in CSF and ratio of Aβ42/Aβ40 were (660.4 ± 265.2) ng/L, (7111.0 ± 1033.4) ng/L, (71.8 ± 51.5) ng/L, and 0.077 ± 0.033, respectively in CAA dementia and (663.6 ± 365.6) ng/L, (5115.0 ± 2931.1) ng/L, (47.7 ± 38.8) ng/L, and 0.192 ± 0.140, respectively in Alzheimer's disease patients. There were no statistically significant differences between CAA dementia and Alzheimer's disease in terms of these CSF biomarkers (all P>0.05).
CONCLUSIONMeasurements of CSF biomarkers may not be helpful in differential diagnosis of CAA and Alzheimer's disease.